Seeking Alpha

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha ...
WebMD

Your Guide to Elahere for Ovarian, Fallopian Tube, or Peritoneal Cancer

Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...
Healthline

Side Effects of Elahere: What You Need to Know

Elahere (mirvetuximab soravtansine-gynx) is a prescription drug used to treat certain types of ovarian, fallopian tube, and peritoneal cancer in adults. Elahere can cause side effects that range from ...
Seeking Alpha

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

NORTH CHICAGO, Ill., Nov. 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE ® (mirvetuximab soravtansine) for the ...